Cargando…

518. Comparable Outcomes of Remdesivir and Sotrovimab among High-risk Patients with Mild to Moderate COVID-19 During the Omicron BA.1 Surge

BACKGROUND: Two independent placebo-controlled clinical trials conducted prior to SARS-CoV-2 Omicron demonstrated that sotrovimab and remdesivir reduced hospitalization among high-risk outpatients with mild to moderate COVID-19. However, their effectiveness have not been directly compared. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chesdachai, Supavit, Rivera (O'Connor), Christina G, Mara, Kristin, Teaford, Hiliary R, Suarez, Maria Gonzalez, Larsen, Jennifer J, Ganesh, Ravindra, Tulledge-Scheitel, Sidna, Razonable, Raymund R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678075/ http://dx.doi.org/10.1093/ofid/ofad500.587

Ejemplares similares

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch
por: Razonable, Raymund R, et al.
Publicado: (2022)

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019
por: Razonable, Raymund R., et al.
Publicado: (2022)

519. Early Transition to Outpatient Remdesivir Increases Patient Satisfaction while Decreasing Hospital Costs
por: Chesdachai, Supavit, et al.
Publicado: (2023)

Clinical outcomes of COVID‐19 treated with remdesivir across the continuum of care
por: Rivera, Christina G., et al.
Publicado: (2023)

Patient Satisfaction With Providers: Do Patient Surveys Give Enough Information to Help Providers Improve Specific Behaviors
por: North, Frederick, et al.
Publicado: (2019)

Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge
por: Bierle, Dennis M., et al.
Publicado: (2021)

Association of provider opioid prescribing practices and the Centers for Medicare and Medicaid Services hierarchical condition category score: A retrospective examination of correlation between the volume of provider-prescribed opioid medications and provider panel complexity
por: North, Frederick, et al.
Publicado: (2017)

Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2
por: Martin-Blondel, Guillaume, et al.
Publicado: (2022)

Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant
por: O’Horo, John C., et al.
Publicado: (2022)

Do primary care providers who prescribe more opioids have higher patient panel satisfaction scores?
por: North, Frederick, et al.
Publicado: (2018)

Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)
por: Tuan, Jessica J., et al.
Publicado: (2023)

Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections
por: Miyashita, Naoyuki, et al.
Publicado: (2023)

Use of sotrovimab in vaccinated versus unvaccinated COVID‐19 patients in a resource‐limited emergency department during the omicron surge
por: Nene, Rahul V., et al.
Publicado: (2023)

Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase
por: Aggarwal, Neil R., et al.
Publicado: (2023)

SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab
por: Stiasny, Karin, et al.
Publicado: (2022)

Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir
por: Martin-Blondel, Guillaume, et al.
Publicado: (2023)

Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
por: Cicchitto, Gaetano, et al.
Publicado: (2022)

Is a switch to a different electronic health record associated with a change in patient satisfaction?
por: North, Frederick, et al.
Publicado: (2020)

Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
por: Razonable, Raymund R., et al.
Publicado: (2021)

Use of a Web-based clinical decision support system to improve abdominal aortic aneurysm screening in a primary care practice
por: Chaudhry, Rajeev, et al.
Publicado: (2012)

Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection
por: Chavarot, Nathalie, et al.
Publicado: (2022)

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
por: Wu, Mary Y., et al.
Publicado: (2023)

Effect of visit length and a clinical decision support tool on abdominal aortic aneurysm screening rates in a primary care practice
por: Eaton, John, et al.
Publicado: (2012)

Population health challenges in primary care: What are the unfinished tasks and who should do them?
por: North, Frederick, et al.
Publicado: (2018)

Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England
por: Harman, Katie, et al.
Publicado: (2023)

Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants
por: Fujimoto, Kana, et al.
Publicado: (2022)

Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab
por: Vellas, Camille, et al.
Publicado: (2022)

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients
por: Destras, Grégory, et al.
Publicado: (2022)

Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19
por: Razonable, Raymund R., et al.
Publicado: (2022)

A Retrospective Analysis of Provider-to-Patient Secure Messages: How Much Are They Increasing, Who Is Doing the Work, and Is the Work Happening After Hours?
por: North, Frederick, et al.
Publicado: (2020)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases
por: Focosi, Daniele, et al.
Publicado: (2022)

Sotrovimab for COVID-19
Publicado: (2021)

Sotrovimab: First Approval
por: Heo, Young-A
Publicado: (2022)

Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
por: Baldi, Federico, et al.
Publicado: (2023)

Omicron’s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals
por: Mader, Anna-Lena, et al.
Publicado: (2022)

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2023)

LB1577. Outcomes of Pregnant Women Exposed to Sotrovimab for the Treatment of COVID-19 in the Omicron Predominant Era (PRESTO)
por: Tuan, Jessica, et al.
Publicado: (2022)

(583) Sotrovimab in Heart Transplant Recipients with Covid-19 in the Omicron Era: A National Transplant Center Experience
por: Garcia, C.N. Perez, et al.
Publicado: (2023)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s2q09tn59khigkq9ai31i730gu